Overview

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

Status:
Completed
Trial end date:
2016-05-05
Target enrollment:
Participant gender:
Summary
A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing
Phase:
Phase 1
Details
Lead Sponsor:
ViiV Healthcare
Collaborator:
GlaxoSmithKline
Treatments:
Fostemsavir